Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Two Phase 3 Trials of Baricitinib for Alopecia Areata
the BRAVE-AA Investigators
Dermatology
Research output
:
Contribution to journal
›
Article
›
peer-review
377
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Two Phase 3 Trials of Baricitinib for Alopecia Areata'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Phase II Trial
100%
Alopecia Areata
100%
Baricitinib
100%
Brave
76%
Placebo
69%
Confidence Interval
30%
Hair Loss
23%
Severity of Alopecia Tool
23%
Scalp Hair
15%
Severe Alopecia Areata
15%
Randomized Placebo-controlled Trial
7%
Janus Kinase 1 (JAK1)
7%
Once-daily
7%
Eyelashes
7%
Autoimmune Disease
7%
Eli Lilly
7%
Low Density
7%
Covalent Inhibitor
7%
Hair Regrowth
7%
Janus Kinase 2 (JAK2)
7%
Scalp
7%
Cytokine Signaling
7%
High-density Lipoprotein Cholesterol (HDL-C)
7%
Creatine Kinase
7%
Acne
7%
High Range
7%
Eyebrow
7%
Pharmacology, Toxicology and Pharmaceutical Science
Baricitinib
100%
Alopecia Areata
100%
Placebo
76%
Hair Loss
23%
Alopecia
23%
Cytokine
7%
High Density Lipoprotein Cholesterol
7%
Acne
7%
Janus Kinase 2
7%
Minoxidil
7%
Creatine Kinase
7%
Janus Kinase 1
7%